cobas® TaqScreen DPX Test

Real-time discrimination of B19V and HAV in one assay

Increasing the safety of human plasma and plasma products

The cobas^® TaqScreen DPX Test a real-time polymerase chain reaction (PCR) assay that detects parvovirus B19 (B19V) and hepatitis A virus (HAV) in human plasma.

Designed to run on the cobas s 201 system, the cobas® TaqScreen DPX Test can help manage the B19V burden in plasma pools and identify HAV-contaminated units while increasing processing efficiency.

Features and benefits

Simultaneously quantifies B19V DNA and detects HAV RNA in real-time
Detects B19V genotypes 1, 2 and 3 and HAV genotypes I, II, III
Available as a B19V DNA-only quantitative assay or a dual/result B19V DNA titer and a HAV RNA reactive/non-reactive
Ready-to-use reagents that do not require freezing

Intended use

US – Indication for Use

The cobas® TaqScreen DPX Test, for use on the cobas s 201 system, is an in vitro nucleic acid amplification test for the direct quantitation of human parvovirus B19 (B19V) DNA (genotypes 1, 2, and 3) and the direct qualitative detection of hepatitis A virus (HAV) RNA (genotypes I, II, and III) in human plasma.

Registration status

*This test is not an FDA-licensed product. It is available to US laboratories with appropriate FDA authorization.

*DPX has been submitted to the FDA as a Master File and will not have a regulatory classification; it will not be cleared, licensed or approved by the FDA.

Real-time discrimination of B19V and HAV in one assay

Increasing the safety of human plasma and plasma products

Features and benefits

Intended use

Registration status

Related assays

Related systems

cobas^® TaqScreen DPX Test